Meclizine for Liver Cancer
(OPTIM Trial)

Recruiting in Palo Alto (17 mi)

+6 other locations

Overseen byTannaz Armaghany, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: Tannaz Armaghnay

No Placebo Group

Approved in 2 Jurisdictions

Trial Summary

What is the purpose of this trial?

This trial tests meclizine, an antihistamine, for treating liver cancer by stopping tumor growth and killing cancer cells. It targets liver cancer patients awaiting surgery or other treatments. Meclizine works by blocking a liver receptor involved in cell growth. Some antihistamines have shown significant antitumor activity alone or with other therapies.

Research Team

Tannaz Armaghany, MD

Principal Investigator

Baylor College of Medicine

Eligibility Criteria

This trial is for adults over 18 with confirmed Hepatocellular carcinoma who haven't had treatment for it yet. They need normal organ/marrow function, measurable disease, and a life expectancy of at least 10 weeks. Candidates must be eligible for certain cancer treatments like surgery or ablation but not liver transplant or other investigational drugs.

Inclusion Criteria

My scans show signs of liver cancer.

Patients should have life expectancy greater than/equal to 10 weeks

I can take care of myself but might not be able to do heavy physical work.

See 8 more

Exclusion Criteria

I do not have any severe illnesses or conditions that are not under control.

I am not pregnant or breastfeeding.

Patients may not be receiving any other concurrent investigational agents

See 8 more

Treatment Details

Interventions

Meclizine (CAR Inverse Agonist)

Trial OverviewThe trial tests Meclizine, an antihistamine used against vertigo and motion sickness, as a potential therapy for liver cancer by acting as a CAR inverse agonist to block tumor growth and induce cell death. Its effects will be measured through changes in specific gene expressions.

Participant Groups

1Treatment groups

Experimental Treatment

Group I: Meclizine 100 mgExperimental Treatment1 Intervention

Meclizine 50 mg will be taken by the patient orally twice daily for a total of 28 days(up to 35 days).

Meclizine is already approved in Canada for the following indications: